Marinomed Biotech AG   Report issue

For profit Phase 3
Founded: Vienna Austria (2006)
Status: Left NME R&D (2016)

Organization Overview

First Clinical Trial
2018
NCT03755557
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Marinomed Biotech AG

Active Ingredients

Drugs in Phase 3 Trials (1)

budesonide (rhinocort) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1